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Abstract
Cell protection against different noxious stimuli like oxidative stress or chemical toxins plays
a central role in the treatment of many diseases. The inducible heme oxygenase isoform,
heme oxygenase-1 (HO-1), is known to protect cells against a variety of harmful conditions
including apoptosis. Because a number of medium strong electrophiles from a series of
α-X-substituted 2’,3,4,4’-tetramethoxychalcones (α-X-TMCs, X = H, F, Cl, Br, I, CN, Me, p-
NO2-C6H4, Ph, p-OMe-C6H4, NO2, CF3, COOEt, COOH) had proven to activate Nrf2 result-
ing in HO-1 induction and inhibit NF-κB downstream target genes, their protective effect
against staurosporine induced apoptosis and reactive oxygen species (ROS) production
was investigated. RAW264.7 macrophages treated with 19 different chalcones (15 α-X-
TMCs, chalcone, 2’-hydroxychalcone, calythropsin and 2’-hydroxy-3,4,4’-trimethoxychal-
cone) prior to staurosporine treatment were analyzed for apoptosis and ROS production, as
well as HO-1 protein expression and enzyme activity. Additionally, Nrf2 and NF-κB activity
was assessed. We found that amongst all tested chalcones only E-α-(4-methoxyphenyl)-
2’,3,4,4'-tetramethoxychalcone (E-α-p-OMe-C6H4-TMC) demonstrated a distinct, statisti-
cally significant antiapoptotic effect in a dose dependent manner, showing no toxic effects,
while its double bond isomer Z-α-p-OMe-C6H4-TMC displayed no significant activity. Also,
E-α-p-OMe-C6H4-TMC induced HO-1 protein expression and increased HO-1 activity,
whilst inhibition of HO-1 by SnPP-IX abolished its antiapoptotic effect. The only weakly elec-
trophilic chalcone E-α-p-OMe-C6H4-TMC reduced the staurosporine triggered formation of
ROS, while inducing the translocation of Nrf2 into the nucleus. Furthermore, staurosporine
induced NF-κB activity was attenuated following E-α-p-OMe-C6H4-TMC treatment. Overall,
E-α-p-OMe-C6H4-TMC demonstrated its effective cytoprotective potential via a non-toxic
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induction of HO-1 in RAW264.7 macrophages. The observed cytoprotective effect may
partly be related to both, the activation of the Nrf2- and inhibition of the NF-κB pathway.
Introduction
While heme oxygenase-2 (HO-2) is constitutively expressed in most tissues, the inducible iso-
form of heme oxygenases HO-1 represents a powerful response to a variety of adverse stimuli
including ischemia-reperfusion injury, hypoxia or toxicity, thus leading to cellular protection
[1]. These cytoprotective effects of HO-1 are caused by various factors. Firstly, HO-1 eliminates
free heme which would otherwise lead to apoptosis in increased concentrations [2, 3]. Sec-
ondly, the cytoprotective function of HO-1 is attributed to its enzymatic reaction products: bili-
verdin, which is further transformed to bilirubin by biliverdin reductase, iron and carbon
monoxide [4, 5]. In general, cytoprotection involves the inhibition of apoptosis and its related
pathways. More and more results indicate that HO-1 induction is a promising therapeutic
regime to treat a variety of diseases [1, 6]. Apart from that, HO-1 may play an important role
in sepsis, where patients suffer from immune suppression as a result of an increased amount of
apoptotic immune cells [7, 8].
The pharmacological application of carbon monoxide or biliverdin/bilirubin can at least
partly replicate HO-1 dependent cytoprotective effects. Low concentrations of inhaled carbon
monoxide can produce anti-inflammatory and antiapoptotic effects, but in-vivo applications of
inhaled carbon monoxide are limited due to its considerable toxicity [5, 9–11]. Therefore car-
bon monoxide releasing molecules (CO-RMs) are considered as attractive alternatives [12–14].
However, there are some disadvantages when looking at the intravenous application of
CO-RMs in humans. After the release of CO, additional degradation products of the CO-RMs
appear which might be toxic. Additionally, depending on the CO release mechanism such as
medium-induced hydrolytic cleavage [13], application of light [15] or the action of cellular pro-
teolytic enzymes [16, 17] different CO forming efficacies and kinetics must be suspected. Thus,
the application of defined doses of CO remains challenging.
Since it is unclear whether the single end products of the HO-1 reaction exert potent thera-
peutic properties or if HO-1 activity itself contributes to the broad range of cytoprotective
effects, we were interested in developing non-cytotoxic HO-1 inducers.
Various structurally different natural products exhibit cytoprotective effects by HO-1 induc-
tion. Amongst them are many examples with an α,β-unsaturated carbonyl unit that can act as
an electrophilic Michael acceptor functionality alkylating reactive cysteine residues. Thereby,
thiol-dependent signaling pathways like the Keap1-Nrf2 or NF-κB pathway can be addressed
assuming an underlying covalent binding mode of action. HO-1 expression is in part regulated
by the transcription factor Nrf2 which interacts with the antioxidant and electrophile response
element (ARE/EpRE) [18]. While Nrf2 is a key player in cytoprotection, NF-κB is one of the
main inflammation-related transcription factors.
In a recent screening study using mostly natural products we found that all tested chalcones
(1,3-diphenylprop-2-enones) gave a 2–6 fold induction of HO-1 activity in RAW264.7 cells [19].
Moreover, we could show that a chemical characterization of natural and synthetic chalcones by
a kinetic thiol reactivity assay could be translated into biological activities such as HO-1 induc-
tion and inhibition of proinflammatory proteins such as iNOS and TNF [20–22], but also
STAT5 inhibition [23]. The chalcones we used were mainly α-X-substituted 2’,3,4,4’-tetra-
methoxychalcones (α-X-TMCs, X = H, F, Cl, Br, I, CN, Me, p-NO2-C6H4, Ph, p-OMe-C6H4,
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CO releasing molecule; DMSO, dimethylsulfoxid;
PBS, phosphate buffered saline; BR, bilirubin; SDS,
sodium dodecyl sulfate; BVR, biliverdin reductase;
NADPH, nicotinamide adenine dinucleotide
phosphate (reduced form); ARE/EpRE, antioxidant/
electrophile response element.
NO2, CF3, COOEt, COOH) whose electrophilic behavior could be fine-tuned by the introduction
of the extra substituent X in the α-position of the α,β-unsaturated carbonyl system [21]. Despite
the fact that clearly electrophilic α-X-TMCs showed the best activities [22] suggesting a covalent
mode of action, some (E)- and (Z)-1,2,3-triarylprop-2-enones (corresponding to α-Ar-chal-
cones) recently proved to be potent selective COX-2 inhibitors [24] as well as microtubule poly-
merization inhibitors [25] indicating a noncovalent binding mode. Since chalcones possess a
high structural variability with the two E/Z double bond isomers, their conformational freedom
(including s-cis vs. s-trans form) as well as quite different electronic properties which depend on
additional substituents, the mechanisms by which they exert their antiapoptotic effect are not
well understood.
We demonstrate that out of a library of 15 electrophilicity-tuned α-X-chalcones (α-
X-TMCs) and 4 further chalcones (chalcone, 2’-hydroxychalcone, calythropsin, 2’-hydroxy-
3,4,4’-trimethoxychalcone (α-H-HC)) the very weak electrophile E-α-p-OMe-C6H4-TMC
exerts an effective cytoprotective potential by non-cytotoxic HO-1 induction in RAW264.7
macrophages via the Nrf2 pathway.
Materials and Methods
Synthesis of chalcone derivatives
α-X-TMCs and other chalcones were prepared as described previously [20, 21]. Z-α-p-OMe-
C6H4-TMC was isolated from the E/Z-isomeric mixture of ~ 80:20 obtained by the same
method as described before [21] in a yield of 15% by column chromatography on silica gel
and preparative TLC using petroleum ether-EtOAc mixtures as the eluents (analytical data see
supporting information). Other compounds were purchased from the following commercial
sources and used without further purification: hemin and gelatin (from cold water fish skin)
from Sigma-Aldrich (Taufkirchen, Germany), NADPH from AppliChem (Darmstadt, Ger-
many), OPD (ortho-phenylenediamine dihydrochloride) from Acros Organics (Geel, Bel-
gium), bilirubin from Frontier Scientific (UK), Triton X-100 from Merck (Darmstadt,
Germany).
Cell culture and experimental protocol
RAW264.7 macrophages (ATCC No. TIB-71) were cultured in RPMI 1640 medium supple-
mented with 10% fetal calf serum, 2 mM glutamine and 1% penicillin and streptomycin at a
constant temperature of 37°C in humidified air containing 5% carbon dioxide. The cells were
plated at least 48 h prior to the initiation of the experiment. Cells were grown to approximately
90% confluence in either 6-well cell culture plates (flow cytometry) or 10 cm cell culture dishes
(protein analysis) under conditions described above. The chalcones were dissolved in DMSO
under light protection (stock solution 10 mM) and were added immediately to the culture
medium obtaining the indicated final concentration. Cells were pre-incubated with chalcones
for 3 h and apoptosis was induced using staurosporine (1.0 μM for 2 h). For each experiment
controls were obtained, keeping cells at standard conditions without intervention. Cells were
harvested for analysis after the 2 h period of staurosporine incubation. For the inhibition of
HO-1 protein expression and enzyme activity SnPP-IX (80 μM for 1 h) was added prior to
incubation with chalcones and induction of apoptosis.
Flow cytometry
Cells (approx. 1 × 105) were washed in phosphate-buffered saline, trypsinized, resuspended in
100 μL binding buffer (0.010 M HEPES, 0.14 M NaCl, 2.5 mM CaCl2, pH 7.4) and stained with
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5 μL FITC annexin-V and propidium iodide (PI). Samples were incubated at room temperature
for 15 min before 400 μL of binding buffer was added. The percentage of annexin-V positive
cells was measured using a flow cytometry device (FACS-Calibur1, Becton-Dickinson, Hei-
delberg, Germany). Fluorescence intensity of RAW264.7 macrophages was measured in fluo-
rescence channel 1 (annexin-V) and in fluorescence channel 3 (propidium iodide). Unstained
cells and those only stained with either annexin-V or propidium iodide served as negative con-
trols for background fluorescence and for set up of compensation settings.
Reactive oxygen species were detected in RAW264.7 cells using the ROS detection kit (Enzo
Life Sciences, Lörrach, Germany). Briefly, cells were harvested (3 × 105), resuspended in 500 μL
of ROS detection solution and stained for 30 min at 37°C in the dark. Samples were measured
immediately using the flow cytometry device. The fluorescent product generated was analyzed
in fluorescence channel 1.
Western blotting
Nuclear and cytoplasmic protein fractions were obtained using a commercially available
extraction kit (Nuclear Extract Kit, Active Motif Europe, Rixensart, Belgium). Equal amounts
of cell extracts (30 μg) were boiled in 5 x SDS loading dye (50% glycerol, 0.50 M dithiothreitol,
350 mM SDS, 7.5 mM bromophenol blue, 250 mM TRIS, pH 6.8) for 5 min and subsequently
subjected to 10% or 13% sodium-dodecyl-sulfate-polyacrylamide gel electrophoresis. Proteins
were transferred onto PVDF membranes (Immobilon-P, Millipore, Schwalbach, Germany)
using wet blotting technique after equilibrating the membranes in methanol (10 s), ddH2O (2
min) and wet blot buffer (20% methanol, 25 mM TRIS, 200 mM glycin, 5 min). After protein
transfer, non-specific binding sites were blocked by incubating membranes in 5% milk powder
dissolved in blocking solution (TBST; 10 mM TRIS, 150 mMNaCl, 0.20% Tween1, pH 8.0)
for 1 h at room temperature. Subsequently, membranes were incubated with the respective pri-
mary antibody at the indicated concentration (HO-1 1:1000; Nrf2 1:1000) both from Cell Sig-
naling (Danvers, MA, USA) overnight at 4°C. After incubation with a horseradish peroxidase-
conjugated anti-rabbit secondary antibody (GE Healthcare, Freiburg, Germany, No. NA9340)
proteins were visualized using the ECL plus Chemiluminescence Kit (GE Healthcare). For nor-
malization, blots were reprobed with β-actin or lamin B1 both from Cell Signaling Technology
(Danvers, MA, USA).
HO-1 activity assay
The assay was performed as previously reported via in-situ formation of bilirubin by HO-1/
BVR activity and quantification of bilirubin by ELISA [19]. Briefly, RAW264.7 macrophages
(8 × 104 cells) were placed in 96-well plates for 24 h and then treated with chalcones for 3 h,
apoptosis was induced by staurosporine afterwards. Controls only received staurosporine to
induce apoptosis and no chalcone treatment. After cell lysis (40 mM TRIS-HCl, pH 7.4, 250
mM sucrose, 137 mMNaCl, 10% (v/v) glycerin, 2.0 mM EDTA, 0.1% (v/v) Triton X-100,
complete protease inhibitor cocktail, Roche Diagnostics, Germany) the HO-1 reaction mixture
(40 mM TRIS-HCl, pH 7.4, 250 mM sucrose, 0.30 mM NADPH, 1.0 ng BVR (biliverdin reduc-
tase, Stressgen, Assay Designs, USA) and 2.5 μM hemin) was applied for 1 h. Bilirubin stan-
dards (0.50–2500 × 10−9 M bilirubin) were prepared in 40 mM TRIS-HCl, pH 7.4, 250 mM
sucrose from a freshly prepared 10 mM stock solution in DMSO and combined with superna-
tant of whole cell lysates from control cells. Bilirubin was quantified by using an excess of the
anti-bilirubin mouse-antibody 24G7 (Shino-Test, Japan, 0.57 μg μL−1 in 1% G-PBS with 0.50
mM sodium salicylate) and subsequently analyzing the unbound 24G7 by ELISA. To trap
24G7 an immunoplate (Nunc, Denmark) coated with a bilirubin-BSA conjugate (0.35 μg
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protein per well) was used. Detection was performed using a HRP-conjugated anti-mouse anti-
body from goat (Rockland, USA; 1:10000) with a freshly prepared substrate solution (0.40 g
mL−1 OPD and 0.40 μL mL−1 30% H2O2 in citrate buffer, pH 5.0). After quenching with
aqueous 3.0 M H2SO4 the absorbance was measured at 492 nm (Multiskan Spectrum, Thermo,
Finland). The sigmoidal calibration curve was fit to a four parameter logistic equation to deter-
mine unknown bilirubin concentrations. HO activity was calculated as pmol bilirubin formed
per hour and per milligram of protein (pmol BR h−1mg−1) and assigned as HO-1 activity since
small underlying HO-2 amounts should stay unchanged.
NF-κB DNA binding activity assay
NF-κB DNA binding activity was analyzed using the TransAM™ NF-κB p65 method (Active
Motif, Rixensart, Belgium), an ELISA-based kit detecting and quantifying the transcription fac-
tor activation. Nuclear protein fraction was obtained as mentioned above and analyzed accord-
ing to the manufacturer’s instructions.
Data analysis
Data was analyzed using a computerized statistical program (SigmaPlot Version 11.0, Systat
Software Inc., San Jose, CA, USA). The Student’s t test or the Mann-Whitney U test (Wilcoxon
rank-sum test) was used to determine whether a difference existed between two groups.
P< 0.05 was considered statistically significant. The results are presented as means (± S.E.M.).
When comparing more than two groups, a Kruskal–Wallis one-way analysis of variance
(ANOVA) on Ranks or a one-way ANOVA was used with post-hoc Holm-Sidak test.
Results
The weak electrophile E-α-p-OMe-C6H4-TMC exerts antiapoptotic
effects
We used our library of α-X-TMCs which possesses a wide range of electrophilicity together
with the medium strong to moderate electrophilic chalcones 2’-hydroxychalcone, calythropsin,
2’-hydroxy-3,4,4’-trimethoxychalcone (α-H-HC) and chalcone itself. The second-order rate
constants k2 for the reaction with the model thiol cysteamine are shown in Figs 1 and 2 [20,
21]. By applying these compounds we can utilize a chemical reactivity range of more than 6
orders of magnitude. When including the previously not described geometric isomer Z-α-p-
OMe-C6H4-TMC the difference in the k2 values between the most electrophilic compound
α-CN-TMC and Z-α-p-OMe-C6H4-TMC is even 300 million fold, since we determined the k2
value for Z-α-p-OMe-C6H4-TMC to be 0.0000196 ± 0.0000021 M
-1s-1.
We examined whether the chalcones exert cytoprotective effects in a model of staurospor-
ine-induced apoptosis in RAW264.7 macrophages. Initiation of apoptosis is inhibited by phos-
phorylation of apoptosis substrates such as caspases. Staurosporine is a broad-spectrum
protein kinase inhibitor [26] and as such is utilized to induce the caspase-dependent mitochon-
drial apoptotic pathway. As a consequence annexin-V is bound on the outer site of the mem-
brane. Exposure to staurosporine increased the percentage of annexin-V positive cells (mean
over all groups = 27.9 ± 4.2%; p< 0.001). Pretreatment of RAW264.7 macrophages using α-
X-TMCs with X = CN, Br, p-NO2-C6H4, I, H F, Me, Ph, NO2, CF3, COOEt, COOH; α-H-HC,
calythropsin and 2’-hydroxychalcone had no diminishing influence on the staurosporine
induced increase in annexin-V positive cells. α-Cl-TMC administration revealed a tendency to
a reduced number of annexin-V positive cells, but failed to reach significance as was found for
chalcone (see Figs 1 and 2).
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Fig 1. Flow cytometric analysis. Effect of different chalcones on staurosporine-induced apoptosis in RAW264.7 macrophages. Cells were pretreated with
the indicated concentrations of chalcones for 3 h, before apoptosis was induced by staurosporine (1 μM for 2 h). Cells were harvested and stained with FITC
annexin-V and propidium iodide. 1 × 104 cells were analyzed in each experiment. (n = 4; mean ± S.E.M.; *** = p < 0.001 untreated vs. staurosporine and
staurosporine vs. 10, 100, 500 and 1000 μM E-α-p-OMe-C6H4-TMC + staurosporine and * = p < 0.05 staurosporine vs. 1 μM E-α-p-OMe-C6H4-TMC +
staurosporine). k2 values for the reaction with the model thiol cysteamine are taken from [21]. N, native; S, staurosporine.
doi:10.1371/journal.pone.0142932.g001
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Fig 2. Flow cytometric analysis. Effect of different chalcones on staurosporine-induced apoptosis in RAW264.7 macrophages. Cells were pretreated with
the indicated concentrations of chalcones for 3 h, apoptosis was induced by 1 μM staurosporine for 2 h afterwards. Cells were stained with FITC annexin-V
and propidium iodide. 1 × 104 cells were analyzed in each experiment. (n = 4; mean ± S.E.M.; *** = p < 0.001). k2 values for the reaction with the model thiol
cysteamine are taken from [20, 21] and for Z-α-p-OMe-C6H4-TMC was determined in this study with 0.0000196 ± 0.0000021 M
-1s-1. N, native; S,
staurosporine.
doi:10.1371/journal.pone.0142932.g002
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E-α-p-OMe-C6H4-TMC pre-treatment demonstrated a significant reduction of annexin-V
positive cells (Fig 1, 1 μM: 20.6 ± 3.2% and 10 μM: 17.1 ± 3.8%; p< 0.001). In contrast, its geo-
metric isomer Z-α-p-OMe-C6H4-TMC showed only a small reduction of annexin-V positive
cells after staurosporine-induced apoptosis at 10 μM, but this effect was not significant (Fig 2A,
22.9 ± 3.5%; p> 0.05).
E-α-p-OMe-C6H4-TMC reduces staurosporine-induced apoptosis in a
dose-dependent manner
Compared to untreated cells, neither DMSO nor the chalcones E-α-p-OMe-C6H4-TMC or Z-
α-p-OMe-C6H4-TMC (each 30 μM for 5 h) showed any increase in annexin-V positive cells
compared to untreated cells (Fig 3, untreated 7.6 ± 1.3; DMSO 7.9 ± 0.04; 30 μM E-α-p-OMe-
C6H4-TMC 7.8 ± 1.7; 30 μM Z-α-p-OMe-C6H4-TMC 6.8 ± 0.7% annexin-V positive / PI nega-
tive cells). Exposure of RAW264.7 cells to 1 μM staurosporine for 2 h increased the amount of
annexin-V positive and propidium iodide (PI) negative cells (Fig 3 A and B, staurosporine
32.9 ± 1.7%) [27]. Pretreatment of RAW264.7 macrophages with E-α-p-OMe-C6H4-TMC
shows a significant and dose dependent reduction in annexin-V positive / PI negative cells in
the context of staurosporine-induced apoptosis (Fig 3A and 3B, staurosporine 32.9 ± 1.7 vs.
staurosporine + 10 μM E-α-p-OMe-C6H4-TMC 10.4 ± 0.7; staurosporine + 20 μM E-α-p-
OMe-C6H4-TMC 8.2 ± 0.9; staurosporine + 30 μμM E-α-p-OMe-C6H4-TMC 7.1 ± 1.2%
annexin-V positive / PI negative cells,  = p< 0.001). Although pretreatment with DMSO
lead to a reduction of annexin-V positive / PI negative cells compared to staurosporine (Fig 3B,
staurosporine 32.9 ± 1.7 vs. staurosporine + DMSO 21.7 ± 1.4% annexin-V positive / PI nega-
tive cells,  = p< 0.001), this reduction differed significantly from the reduction achieved by
the pretreatment with E-α-p-OMe-C6H4-TMC (Fig 3A and 3B, staurosporine + DMSO
21.7 ± 1.4 vs. staurosporine + 10/20/30 μM E-α-p-OMe-C6H4-TMC: 10.4 ± 0.7; 8.2 ± 0.9;
7.1 ± 1.2% annexin-V positive / PI negative cells, all  = p< 0.001).
In contrast, pretreatment with 30 μM of the isomeric Z-α-p-OMe-C6H4-TMC prior to
staurosporine treatment gave no significant reduction in annexin-V positive / PI negative cells
compared to the pretreatment with DMSO + staurosporine (Fig 3A and 3B, staurosporine +
DMSO 21.7 ± 1.4 vs. staurosporine + 30 μM Z-α-p-OMe-C6H4-TMC 19.7 ± 0.4% annexin-V
positive / PI negative cells; not significant). The comparison of E- and Z-α-p-OMe-C6H4-TMC
at equal amounts revealed their clear difference in activity (Fig 3A, and 3B, staurosporine +
30 μM E-α-p-OMe-C6H4-TMC 7.1 ± 1.2 vs. staurosporine + 30 μM Z-α-p-OMe-C6H4-TMC
19.7 ± 0.4% annexin-V positive / PI negative cells,  = p< 0.001).
E-α-p-OMe-C6H4-TMC exhibits no toxic effects
Exposure of RAW264.7 macrophages to the indicated concentrations of E-α-p-OMe-C6H4-
TMC for 3 and 5 h did not demonstrate any toxic effects (Fig 4A–4C, displaying the results of
5 h pretreatment; 3 h data not shown).
To measure the toxicity of E-α-p-OMe-C6H4-TMC we incubated RAW264.7 macrophages
for 5 h in medium containing a range of 10 to 60 μM E-α-p-OMe-C6H4-TMC. Analysis
revealed no increase in apoptotic cells judged by annexin-V positive / PI negative
characteristics (Fig 4B: untreated 8.4 ± 0.9 vs. 10 μM E-α-p-OMe-C6H4-TMC 7.5 ± 0.4 vs.
20 μM E-α-p-OMe-C6H4-TMC 8.3 ± 0.5 vs. 30 μM E-α-p-OMe-C6H4-TMC 7.8 ± 3.9 vs.
60 μM E-α-p-OMe-C6H4-TMC 9.1±0.1% annexin-V positive / PI negative cells, not signifi-
cant). Also, no necrotic cells were found as assigned with annexin-V positive / PI positive
staining (Fig 4C: untreated 3.4 ±0 .1 vs. 10 μM E-α-p-OMe-C6H4-TMC 3.1 ± 0.5 vs. 20 μM
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E-α-p-OMe-C6H4-TMC 3.2 ± 0.4 vs. 30 μM E-α-p-OMe-C6H4-TMC 3.2 ± 0.3 vs. 60 μM E-α-
p-OMe-C6H4-TMC 3.2 ± 0.6% annexin-V positive / PI positive cells, not significant).
Fig 3. Flow cytometric analysis.RAW264.7 cells were pretreated with either E-α-p-OMe-C6H4-TMC or Z-α-p-OMe-C6H4-TMC (short: E-pOMe, Z-pOMe) for
3 h. Apoptosis was induced using staurosporine (1 μM for 2 h). A. Representative experiment after FITC annexin-V and propidium iodide (PI) staining. 1 × 104
cells were analyzed in each experiment. B. Effect of E-α-p-OMe-C6H4-TMC and Z-α-p-OMe-C6H4-TMC on cytoprotection (n = 6; mean ± S.E.M.; *** =
p < 0.001).
doi:10.1371/journal.pone.0142932.g003
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E-α-p-OMe-C6H4-TMC induces HO-1 protein expression in a dose-
dependent manner
RAW264.7 macrophages treated with 30 μM E-α-p-OMe-C6H4-TMC without induction of
apoptosis showed a significant increase in HO-1 protein expression compared to cells treated
with DMSO alone (Fig 5B: DMSO 1.01 ± 0.13 vs. 30 μM E-α-p-OMe-C6H4-TMC 1.76 ± 0.33
fold change HO-1/β-actin; n = 5;  = p< 0.05). Treating cells only with staurosporine or in
Fig 4. Flow cytometric analysis. RAW264.7 cells were treated with E-α-p-OMe-C6H4-TMC (short: E-pOMe) (10, 20, 30 and 60 μM) alone for 5 h. A.
Representative experiment after FITC annexin-V and propidium iodide staining (PI). 1 × 104 cells were analyzed in each experiment. B. Non-toxic effect of E-
α-p-OMe-C6H4-TMC. Apoptotic cells (annexin-V positive/ PI negative) were analyzed (n = 4; mean ± S.E.M.). C. Non-toxic effect of E-α-p-OMe-C6H4-TMC.
Necrotic cells (annexin-V positive / PI positive) were analyzed (n = 4; mean ± S.E.M.).
doi:10.1371/journal.pone.0142932.g004
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combination with DMSO had no effect on HO-1 protein expression (Fig 5B; staurosporine
1.01 ± 0.19 vs. staurosporine + DMSO 1.3 ± 0.4 fold change HO-1/β-actin; not significant).
Since E-α-p-OMe-C6H4-TMC is dissolved in DMSO, pretreatment of macrophages with
DMSO before induction of apoptosis served as a negative control. Pretreatment of cells with
indicated concentrations of E-α-p-OMe-C6H4-TMC for 3 h prior to induction of apoptosis
resulted in a dose dependent and significant increase of HO-1 protein expression (Fig 5A, lanes
3 and 5 vs. 6, 7 and 8 and Fig 5B, staurosporine 1.01 ± 0.19 and staurosporine + DMSO
1.3 ± 0.4 vs. staurosporine + 10/20/30 M E-α-p-OMe-C6H4-TMC: 1.8 ± 0.6; 2.2 ± 0.54 and
2.26 ± 0.8 fold change HO-1/β-actin,  = p< 0.05;  = p< 0.001).
To proof if HO-1 protein expression is E-α-p-OMe-C6H4-TMC-dependent, we analyzed
whether blocking HO-1 using the HO-1 inhibitor SnPP-IX abolishes the effect of E-α-p-OMe-
C6H4-TMC. Cells pretreated with SnPP-IX prior to 30 μM E-α-p-OMe-C6H4-TMC and staur-
osporine treatment showed a significant reduction of the HO-1 protein expression (Fig 5C,
lanes 6 vs. 7, Fig 5D, staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 2.65 ± 0.12 vs. SnPP-IX +
staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 1.34 ± 0.25 fold change HO-1/β-actin;  =
p< 0.001).
Fig 5. Western Blot analysis. A. RAW264.7 cells were pretreated with E-α-p-OMe-C6H4-TMC (short: E-pOMe) for 3 h, apoptosis was induced using
staurosporine (1 μM for 2 h). Whole-cell extracts were prepared and HO-1 protein expression levels were analyzed. The image is representative of five
independent experiments that showed similar results. B. Densitometric analysis of A, optical density of HO-1 normalized against β-actin (n = 5; mean ± S.E.
M.; *** = p < 0.001; * = p < 0.05); C. RAW264.7 cells were pretreated with SnPP-IX (80 μM for 1 h) to inhibit HO-1 expression prior to the treatment with E-α-
p-OMe-C6H4-TMC for 3 h, apoptosis was induced using staurosporine (1 μM for 2 h). Whole-cell extracts were prepared and HO-1 protein expression levels
were analyzed. The image is representative of five independent experiments that showed similar results. D. Densitometric analysis of C, optical density of
HO-1 normalized against β-actin (n = 5; mean ± S.E.M.; *** = p < 0.001).
doi:10.1371/journal.pone.0142932.g005
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E-α-p-OMe-C6H4-TMC induces HO-1 activity and exerts a HO-1
dependent cytoprotection
Apart from the HO-1 protein expression, HO-1 activity was analyzed. Cells treated with 30 μM
E-α-p-OMe-C6H4-TMC without induction of apoptosis demonstrated a significant increase in
HO-1 activity compared to untreated cells (Fig 6A, untreated 1050 ± 339 vs. 30 μM E-α-p-
OMe-C6H4-TMC 1780 ± 153 HO activity [pmol BR h
-1mg-1 protein];  = p< 0.05).
Similarly to the results obtained for HO-1 protein expression, pretreatment of cells with
increasing concentrations of E-α-p-OMe-C6H4-TMC for 3 h and induction of apoptosis
resulted in a dose dependent and significant increase of HO-1 activity (Fig 6A, staurosporine
1270 ± 583 vs. staurosporine + 10, 20, 30 μM E-α-p-OMe-C6H4-TMC 1340 ± 530, 1870 ± 845
and 2140 ± 331 HO-1 activity [pmol BR h-1mg-1 protein];  = p< 0.05). Using SnPP-IX, prior
to E-α-p-OMe-C6H4-TMC and staurosporine treatment abolished the activity of HO-1 (Fig
6A, staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 2140 ± 331 vs. SnPP-IX + staurosporine +
30 μM E-α-p-OMe-C6H4-TMC 144 ± 35 HO-1 activity [pmol BR h
-1mg-1 protein];  =
p< 0.001).
To answer the question, if E-α-p-OMe-C6H4-TMC-dependent HO-1 induction is responsi-
ble for cytoprotection, we analyzed the percentage of annexin-V positive / PI negative cells
with and without SnPP-IX (Fig 6B). While staurosporine-induced apoptosis was significantly
reduced by pretreating cells with E-α-p-OMe-C6H4-TMC, this effect was abolished using
SnPP-IX (Fig 6B, staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 13.1 ± 1.4 vs. SnPP-IX +
staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 31.7 ± 2.7% annexin-V positive / PI negative
cells;  = p< 0.001)
Fig 6. A. HO-1 activity assay. RAW264.7 cells were pretreated with SnPP-IX (80 μM for 1 h) to inhibit HO-1 activity prior to the treatment E-α-p-OMe-
C6H4-TMC (short: E-pOMe) for 3 h, apoptosis was induced using staurosporine (1 μM for 2 h). Whole-cell protein extracts were prepared and HO
activity wasmeasured by ELISA-based bilirubin quantification; B. Flow cytometric analysis. RAW264.7 cells were pretreated with SnPP-IX (80 μM
for 1 h) to inhibit HO-1 activity prior to the treatment with E-α-p-OMe-C6H4-TMC for 3 h, apoptosis was induced using staurosporine (1 μM for 2 h).
Cells were stained with FITC annexin-V and propidium iodide to mark apoptotic cells. 1 × 104 cells were analyzed in each experiment (n = 4;
mean ± S.E.M.; * = p < 0.05).
doi:10.1371/journal.pone.0142932.g006
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E-α-p-OMe-C6H4-TMC reduces the formation of reactive oxygen
species
ROS production was induced using staurosporine. Compared to untreated cells application of
staurosporine lead to a significant increase in ROS production (Fig 7A, and 7B, untreated
30.5 ± 0.9 vs. staurosporine 73.7 ± 6.9% ROS positive cells;  = p< 0.001) Pretreatment
with E-α-p-OMe-C6H4-TMC reduced ROS formation significantly (Fig 7A and 7B, staurospor-
ine 73.7 ± 6.9 vs. staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 40.9 ± 1.5% ROS positive
cells;  = p< 0.05). To exclude the possibility that this effect is caused by DMSO we compared
ROS production induced by staurosporine in cells pretreated with DMSO alone to cells pre-
treated with E-α-p-OMe-C6H4-TMC dissolved in DMSO (Fig 7A and 7B, staurosporine +
DMSO 54.4 ± 2.5 vs. staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 40.9 ± 1.5% ROS positive
cells;  = p< 0.05).
E-α-p-OMe-C6H4-TMC induces the translocation of Nrf2 and reduces
NF-κB activity
To elucidate a possible mechanism leading to the proposed cytoprotective effects via HO-1
induction by E-α-p-OMe-C6H4-TMC, we analyzed the translocation of the transcription factor
Nrf2. Untreated cells compared to cells treated with E-α-p-OMe-C6H4-TMC alone showed a
significant translocation of Nrf2 into the nucleus (Fig 8A, Lane 1 vs. 2; Fig 8B, untreated nor-
malized to 1 vs. 30 μM E-α-p-OMe-C6H4-TMC 3.3 ± 2.8 fold change Nrf2/Lamin B1,  =
p< 0.05). We did not detect an increased Nrf2 translocation after staurosporine induction
alone, whereas pretreatment with E-α-p-OMe-C6H4-TMC before induction of apoptosis
caused a significant nuclear translocation of Nrf2 (Fig 8A and 8B, staurosporine 1.6 ± 0.5 vs.
staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 3.2 ± 0.4 fold change Nrf2/Lamin B1;  =
p< 0.01). The cytosolic extracts did not show any significant differences regarding Nrf2
expression levels (Fig 8A and 8C). Fig 8D demonstrates the nuclear to cytosolic ratio of Nrf2
and in this way combines the results highlighted in Fig 8B and 8C. Macrophages treated with
Fig 7. Total ROS detection by flow cytometric analysis.RAW264.7 cells were pretreated with E-α-p-OMe-C6H4-TMC (short: E-pOMe) for 3 h, ROS
production was induced using staurosporine (1 μM for 2 h); A. Representative experiment after intracellular ROS staining. 1 × 104 cells were analyzed in
each experiment; B. E-α-p-OMe-C6H4-TMCmediated effect on intracellular ROS production (n = 6; mean ± S.E.M.; * = p < 0.05).
doi:10.1371/journal.pone.0142932.g007
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E-α-p-OMe-C6H4-TMC revealed a significantly increased nuclear to cytosolic ratio of Nrf2
compared to untreated cells, whereas E-α-p-OMe-C6H4-TMC pretreatment before induction
of apoptosis lead to a significant increased ratio compared to staurosporine alone (Fig 8D,
untreated normalized to 1 vs. 30 μM E-α-p-OMe-C6H4-TMC 2.4 ± 1.5; staurosporine 1.5 ± 0.6
vs. staurosporine + 30 μM E-α-p-OMe-C6H4-TMC 4.3 ± 1.9 Nrf2 ratio nuclear/cytosolic,  =
p< 0.05).
To analyze NF-κB DNA binding activity, we prepared nuclear extracts after pretreating
macrophages with E-α-p-OMe-C6H4-TMC and staurosporine. In contrast to the results of
Nrf2 expression, treatment with E-α-p-OMe-C6H4-TMC alone lead to a significantly
decreased binding activity of NF-κB compared to untreated cells (Fig 8E, untreated 0.41 ± 0.08
vs. 30 μM E-α-p-OMe-C6H4-TMC 0.28 ± 0.03 NF-κB DNA binding activity OD [450 nm];  =
p< 0.05). Staurosporine caused a significantly increased binding activity of NF-κB compared
to untreated cells. This effect is significantly reduced when cells are pretreated with E-α-p-
OMe-C6H4-TMC prior to the induction of apoptosis (Fig 8E, staurosporine 0.77 ± 0.05
Fig 8. Effects of E-α-p-OMe-C6H4-TMC (short: E-pOMe) on Nrf2 expression after staurosporine treatment.RAW264.7 cells were pretreated with E-α-p-
OMe-C6H4-TMC (30 μM) for 3 h, followed by staurosporine (1 μM for 2 h). Nuclear and cytosolic cell extracts were prepared and Nrf2 expression was
measured byWestern blot analysis. A. The image is representative of four independent experiments that showed similar results; B. Densitometric analysis of
nuclear extracts, optical density of Nrf2 normalized against Lamin B1 (n = 4; mean ± S.E.M.; ** = p < 0.005); C. Densitometric analysis of cytosolic extracts,
optical density of Nrf2 normalized against β-actin (n = 4; mean ± S.E.M.); D. Densitometric analysis of nuclear Nrf2 normalized to cytosolic Nrf2 (n = 4;
mean ± S.E.M.; * = p < 0.05); E. Effects of E-α-p-OMe-C6H4-TMC on NF-κB DNA binding activity after staurosporine treatment. RAW264.7 cells were
pretreated with E-α-p-OMe-C6H4-TMC (30 μM) for 3 h, followed by staurosporine (1 μM for 2 h). Nuclear extracts were prepared and NF-κB DNA binding
activity was measured (n = 4; mean ± S.E.M.; * = p < 0.05).
doi:10.1371/journal.pone.0142932.g008
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vs. 30 μM E-α-p-OMe-C6H4-TMC + staurosporine 0.57 ± 0.17 NF-κB DNA binding activity
OD [450 nm];  = p< 0.05).
The two double bond isomers E-α-p-OMe-C6H4-TMC and Z-α-p-OMe-
C6H4-TMC possess significantly different 3-dimentional structures
From the X-ray analysis of the two solid state structures it becomes clear that both geometric
isomers adopt two very different structures. While E-α-p-OMe-C6H4-TMC (Fig 9A) is found
in the s-trans conformation (Fig 9A), its isomer Z-α-p-OMe-C6H4-TMC crystalizes in an
intermediate form which is in between the s-cis and s-trans conformation (Fig 9B and 9C). For
Z-α-p-OMe-C6H4-TMC it appears that the B-ring of the chalcone scaffold and the p-methoxy-
phenyl X substituent are in one plane with the 2,3 double bond; and, in that sense form a trans-
stilbene-like unit. Moreover, the plane of the chalcone A-ring together with the carbonyl car-
bon is placed orthogonal to the trans-stilbene-like unit forming the main conjugated system.
E-α-p-OMe-C6H4-TMC on the other hand has a very similar solid state structure compared
to the α-X-TMC halogen compounds with X = F, Cl, Br and I [21], which also are found in the
s-trans conformation and proved to be very good to moderate electrophiles.
Fig 9. Solid-state structures from X-ray analysis of: A. E-α-p-OMe-C6H4-TMC. One out of four, essentially the same, molecules from the unit cell is
shown. B,C. Z-α-p-OMe-C6H4-TMC. The two different conformers from the unit cell are shown. Ellipsoids are drawn at the 50% probability levels.
doi:10.1371/journal.pone.0142932.g009
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Discussion
To date, many natural products with α,β-unsaturated carbonyl units (i.e. natural chalcones and
flavonoids) are described as antioxidants with beneficial biological potential [28, 29]. We tested
some α-H-chalcones, some with free phenolic hydroxyl groups, together with a previously syn-
thesized library of α-X-substituted tetramethoxychalcones (α-X-TMCs) to examine their ther-
apeutic potential. For the α-X-TMCs it was particularly important to survey their activity
depending on the substituents in the α-position which directly influence their electrophilicity,
but also 3D-structure. Among the 14 α-X-TMCs, E-α-p-OMe-C6H4-TMC displayed the most
promising potential as a new therapeutic agent, demonstrating a highly significant reduction of
annexin-V positive cells. All other tested chalcones showed either no protection or even an
increase in apoptosis.
Pretreatment of RAW264.7 macrophages with 10, 20 or 30 μM of E-α-p-OMe-C6H4-TMC
induced a significant dose-dependent reduction of apoptotic cells after staurosporine treat-
ment. Applying higher concentrations of E-α-p-OMe-C6H4-TMC up 1000 μM did not lead to
any additional anti-apoptotic effect. To challenge the non-cytotoxic properties of E-α-p-OMe-
C6H4-TMC, we doubled the concentration with the highest anti-apoptotic effect without an
increase of apoptosis or necrosis. As pretreatment with Z-α-p-OMe-C6H4-TMC did not show
a significant antiapoptotic effect compared to the pretreatment with DMSO, we cannot rule
out that the observed antiapoptotic trend of Z-α-p-OMe-C6H4-TMC is caused by the solvent
DMSO. Alternatively, it might be possible that small amounts of the other double bond isomer
are being formed during handling of solutions or in the cell to contribute to this minor effect.
After verification of its anti-apoptotic effect we examined the upregulation and activity of
cytoprotective enzymes whereby HO-1 overexpression and activity showed a highly significant
dose-dependency. As a proof of principle, inhibition of HO-1 abolished the antiapoptotic effect
of E-α-p-OMe-C6H4-TMC. In recent years many in-vitro and in-vivo studies have been con-
ducted on CO application as a gas or intravenous [30–32]. For intravenous application CO
may be linked to metal complexes (CO-RMs) [13, 33, 34]. In general HO-1 cytoprotection is
not exclusively dependent on CO and on biliverdin/bilirubin. Moreover, HO-1 acts as an anti-
oxidant reducing the cellular pool of free heme and iron [35]. We are convinced that non-cyto-
toxic HO-1 induction is more potent in cyto- and organ protection then just imitating its
natural activity by adding biliverdin, bilirubin or CO.
Therapeutic strategies aimed at utilizing the cytoprotective effects of HO-1 are hindered by
the fact that most pharmacological inducers negatively influence organ function by themselves
and are not available for application in patients because of their immense toxicity and undesir-
able side effects [36]. As a consequence in-vitro and in-vivo studies utilizing drugs that are
applied in daily clinical practice were conducted. Inhalation anesthetics like sevoflurane and
isoflurane were used to induce HO-1 in-vitro and in-vivo; a potential problem concerning
these studies is the fact that the high concentrations used in the experiments are far away from
the concentrations applied in daily clinical practice [37–39]. It is most tempting to speculate
about in-vivo effects of E-α-p-OMe-C6H4-TMC. Since in-vitro concentrations of 10 to
1000 μM have shown no toxic or any other adverse effects, the possible therapeutic range is
huge. As no concentration have been tested in animals so far, dose dependency of E-α-p-OMe-
C6H4-TMC concerning HO-1 induction must be tested individually.
Antioxidant activity refers to the prevention or retardation of the oxidation of other mole-
cules, which is usually caused by reactive oxygen species. E-α-p-OMe-C6H4-TMC decreased
ROS levels after induction of apoptosis. To exclude the possibility that the reduction of ROS is
caused by the solvent DMSO, pretreatment with DMSO before staurosporine induction was
used as negative control. Since E-α-p-OMe-C6H4-TMC is a relatively electron-rich compound
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it could be argued that it might act as a direct reducing agent to neutralize radicals. Due to the
lack of free hydroxyl groups, which are typical for natural antioxidative flavonoids such as chal-
cones, that is less likely, but a radical entrapment through the enone system can be envisioned.
Finally, we examined whether HO-1 induction is caused by an increased Nrf2 activation.
Nrf2 plays a crucial role in the expression of cytoprotective enzymes among which HO-1 is one
of the most important ones [18]. In its inactivated form Nrf2 is bound to its inhibitor Keap1.
Certain stimuli lead to a release of Nrf2 from its inhibitor Keap1 resulting in translocation of
Nrf2 into the nucleus [40, 41]. Our results show a significant nuclear translocation of Nrf2
after E-α-p-OMe-C6H4-TMC treatment. Further studies are needed to examine the exact
mechanism that leads to the described translocation.
The transcription factor NF-κB is another central key player looking at apoptosis and its
mechanisms [42, 43]. It is essential for the function of our immune system and is responsible
for the expression of cytokines, growth factors and proapoptotic factors. According to present
studies, the function of NF-κB regarding apoptosis remains inconsistent. There are many atyp-
ical inducers of apoptosis which act through NF-κB activation, such as UV radiation, H2O2 or
some anticancer drugs [44]. Apart from that inhibition of NF-κB activation leads to neuropro-
tection [45]. In addition, HO-1 seems to be a down-modulator of NF-κB activation without
affecting the expression of cytoprotective genes [46]. Our results show that E-α-p-OMe-C6H4-
TMC treatment and pretreatment just prior to induction of apoptosis leads to a significant
reduction of NF-κB activity.
In our previous work using 1 or 5 μM E-α-p-OMe-C6H4-TMC we were not able to prove
any anti-inflammatory effects in RAW264.7 cells based on Nrf2-activation [22]. Using now
higher concentrations for both E- and its newly synthesized isomer Z-α-p-OMe-C6H4-TMC,
only the E-isomer proved antiapoptotic and anti-inflammatory effects via Nrf2-, NF-κB- and
ROS-dependent pathways. Since we could demonstrate that both isomers can act as electro-
philes, but are very different in their electrophilicity—namely by a factor of 440 less for the Z-
isomer—it could be argued that the Z-isomer is a too weak electrophile to make use of this
chemical property within the cell. That could be one reason for the lack of activity in Z-α-p-
OMe-C6H4-TMC. On the contrary for E-α-p-OMe-C6H4-TMC it can be argued that its biolog-
ical activity might indeed depend in part on the intrinsic alkylation power of the Michael
acceptor unit present in its enone system. But, since its k2 value is very low the often feared
electrophilicity-related non-specific toxicity does not come into play and opens the door for a
potential clinical use.
Moreover, since one has to assume that the third aromatic ring is essential to provide more
interactions, it is worthwhile to look closer at the other two 1,2,3-triaryl-compounds in our
library, namely α-p-NO2-C6H4-TMC and α-Ph-TMC (both are E-isomers). Despite their pro-
nounced difference in their electrophilicities both are neither toxic nor do they reduce stauros-
porine-induced apoptosis. This indicates that the methoxy group in E-α-p-OMe-C6H4-TMC
plays an important role creating non-covalent binding interactions.
To understand the quite pronounced difference in the chemical reactivity of E-α-p-OMe-
C6H4-TMC vs. Z-α-p-OMe-C6H4-TMC one can draw some analogies from the X-ray struc-
tures of the α-halogen-TMCs. Their electrophile behavior mainly depends on the electronic
nature of the halogen substituents. More precisely, upon a weakening of the resonance effect
due to the longer halogen bonds from F, Cl to Br the inductive effect lead to a better electrophi-
licity in Br than in Cl and in α-F-TMC. The more sterically demanding iodo substituent gave a
more twisted conjugated system which lowered the kinetic activity. This effect can be antici-
pated in a similar way for Z-α-p-OMe-C6H4-TMC, but with a much stronger disruption of the
conjugation of the enone system towards a main conjugation via the trans-stilbene unit involv-
ing the X-aromatic group and the B-ring. This reduced conjugation with the carbonyl carbon
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caused a very weak electrophilicity for Z-α-p-OMe-C6H4-TMC. Furthermore, the great differ-
ences in the 3D-structure most likely play a distinct role when binding to a particular site is
required for activity. The alkylation ability might kick in once a certain residence time is
reached at a potential alkylation site. In E-α-p-OMe-C6H4-TMC this potential interplay seems
to be balanced in a way so that unspecific toxicity does not become relevant.
In conclusion, we utilized 19 chalcones out of which one shows a highly significant antia-
poptotic effect in RAW264.7 macrophages in a dose-dependent manner. We demonstrate that
this effect is caused by a dose-dependent induction of HO-1 via Nrf2 presenting one of the key
mechanisms in cyto- and organ protection. Based on our results we are convinced that E-α-p-
OMe-C6H4-TMC provides promising therapeutic potential for cyto- or even organ protection.
Further studies are needed to verify our results in in-vivomodels addressing these questions.
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